SGP SpyGlass Pharma, Inc.
Price Chart
Executive Summary
SpyGlass Pharma reported its Q4 and full-year 2025 financial results alongside key clinical and corporate updates, including the successful $172.5 million IPO in February 2026. The company highlighted positive 12-month Phase 1/2 data for its BIM-IOL System, showing sustained intraocular pressure control and elimination of eye drops in 97% of patients. Despite increasing R&D and G&A expenses, the IPO has extended its cash runway to fund operations through 2028.
Key Financial Metrics
Actionable Insight
Investors should monitor upcoming milestones, including the initiation of the BIM-DRS first-in-human trial in H2 2026 and four-year follow-up data from the FIH trial in Q4 2026. The strong clinical data and extended cash runway reduce near-term dilution risk and support long-term value creation if Phase 3 trials succeed.
Key Facts
- Raised $172.5 million in gross proceeds from IPO completed on February 9, 2026.
- 12-month Phase 1/2 trial data show 98% of patients on the 78-mcg dose of BIM-IOL System were free of IOP-lowering eye drops, with a 34% mean IOP reduction and no serious ocular adverse events.
- Cash, cash equivalents, and short-term investments totaled $107.4 million as of December 31, 2025, with post-IPO cash expected to fund operations through 2028.
- Net loss was $12.6 million for Q4 2025 ($5.72/share), up from $8.4 million ($4.58/share) in Q4 2024.
- Phase 3 trials (SGP-005 and SGP-006) for BIM-IOL System are underway, with first patients randomized in January 2026.
Financial Impact
The $172.5 million IPO significantly strengthens the balance sheet and extends cash runway to 2028, enabling full funding of Phase 3 trials and a first-in-human trial for BIM-DRS. However, net losses increased to $39.9 million in 2025 from $29.2 million in 2024 due to higher R&D and G&A spending.
Risk Factors
- Clinical trial delays or adverse results in ongoing Phase 3 studies could negatively impact valuation.
- As a pre-revenue biopharma company, SpyGlass Pharma remains dependent on successful clinical development and regulatory approval.
- Increased operating losses may continue as R&D and commercial preparation costs rise.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263396 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 24, 2026
19d ago
|
ANALYST-UPGRADE
| $26.82 $27.20 | ▲ +1.42% | ▲ +2.32% | $18.44 (−31.25%) |
|
May 14, 2026
29d ago
|
8-K
| $23.21 $20.84 | ▼ −10.21% | ▼ −11.17% | $18.44 (−20.55%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $24.94 $23.52 | ▼ −5.69% | ▼ −6.25% | $18.44 (−26.06%) |
|
Mar 26, 2026
11w ago
|
Press Release
| $22.61 $22.65 | ▲ +0.18% | ▼ −3.69% | $18.44 (−18.44%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $27.12 $27.10 | ▼ −0.07% | ▲ +1.28% | $18.44 (−32.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access